Fredrick Wigley
New England Journal of Medicine · 2000–2016
A researcher in the Science corpus: 5 papers; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Whom Fredrick Wigley trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Fredrick Wigley overall
Papers from Fredrick Wigley's perspective
Ordered by how strongly the researchers Fredrick Wigley trusts endorse each paper. Same corpus, a different order for every researcher.
- Comorbidity Clusters in Autism Spectrum Disorders: An Electronic Health Record Time-Series Analysis
- Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium (Science Translational Medicine)
- Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets (PLoS ONE)
- Stimulating the adoption of health information technology. (West Virginia Medical Journal)
- Using electronic health records to drive discovery in disease genomics
- Marble: high-throughput phenotyping from electronic health records via sparse nonnegative tensor factorization
- Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. (The Lancet)
- Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. (Journal of Allergy and Clinical Immunology)
- Group-based trajectory modeling in clinical research. (Annual Review of Clinical Psychology)
- Naïve Electronic Health Record phenotype identification for Rheumatoid arthritis.
Their papers
- Clustering Longitudinal Clinical Marker Trajectories from Electronic Health Data: Applications to Phenotyping and Endotype Discovery (2015) — 116 citations
- Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial (2016) — 602 citations
- A Probabilistic Graphical Model for Individualizing Prognosis in Chronic, Complex Diseases (2015)
- Cyclophosphamide versus placebo in scleroderma lung disease. (2006) — 1,467 citations
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease (2000) — 955 citations